CN103826608A - 脱氧胆酸和其盐的制剂 - Google Patents

脱氧胆酸和其盐的制剂 Download PDF

Info

Publication number: CN103826608A
Authority: CN; China
Prior art keywords: compositions; deoxycholate; precipitation; composition; sodium
Prior art date: 2011-08-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201180072842.2A

Other languages

English (en)

Chinese (zh)

Inventor

罗伯特·埃米尔·阿德热

杰弗里·多格拉斯·韦伯斯特

罗伯特·M·莫里亚蒂

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kythera Biopharmaceuticals LLC

Original Assignee

Kythera Biopharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-23

Filing date

2011-08-23

Publication date

2014-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45569726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103826608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-23 Application filed by Kythera Biopharmaceuticals LLC filed Critical Kythera Biopharmaceuticals LLC

2011-08-23 Priority to CN201810400642.9A priority Critical patent/CN108619089A/zh

2011-08-23 Priority to CN201810403291.7A priority patent/CN108743522A/zh

2014-05-28 Publication of CN103826608A publication Critical patent/CN103826608A/zh

Status Pending legal-status Critical Current

Links

KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 title claims abstract description 121
239000000203 mixture Substances 0.000 title claims abstract description 107
229960003964 deoxycholic acid Drugs 0.000 title claims abstract description 83
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 title claims abstract description 47
150000003839 salts Chemical class 0.000 title claims abstract description 27
238000009472 formulation Methods 0.000 title description 31
238000001556 precipitation Methods 0.000 claims abstract description 43
238000000034 method Methods 0.000 claims abstract description 34
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 79
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
235000019445 benzyl alcohol Nutrition 0.000 claims description 26
239000007864 aqueous solution Substances 0.000 claims description 20
239000011780 sodium chloride Substances 0.000 claims description 16
239000000872 buffer Substances 0.000 claims description 15
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
210000001789 adipocyte Anatomy 0.000 claims description 9
229910052783 alkali metal Inorganic materials 0.000 claims description 6
-1 alkali metal salt Chemical class 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
210000004027 cell Anatomy 0.000 claims description 2
238000010586 diagram Methods 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
229960004217 benzyl alcohol Drugs 0.000 claims 4
230000002421 anti-septic effect Effects 0.000 claims 3
238000005336 cracking Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 10
230000000087 stabilizing effect Effects 0.000 abstract description 3
239000000243 solution Substances 0.000 description 53
229940009976 deoxycholate Drugs 0.000 description 38
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
239000002585 base Substances 0.000 description 21
239000013011 aqueous formulation Substances 0.000 description 17
150000001875 compounds Chemical class 0.000 description 16
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
239000002244 precipitate Substances 0.000 description 13
101710151321 Melanostatin Proteins 0.000 description 12
102400000064 Neuropeptide Y Human genes 0.000 description 12
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 11
239000002464 receptor antagonist Substances 0.000 description 11
229940044551 receptor antagonist Drugs 0.000 description 11
229910052751 metal Inorganic materials 0.000 description 10
239000002184 metal Substances 0.000 description 10
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
239000008363 phosphate buffer Substances 0.000 description 8
239000003755 preservative agent Substances 0.000 description 8
238000010254 subcutaneous injection Methods 0.000 description 8
239000007929 subcutaneous injection Substances 0.000 description 8
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 7
239000008186 active pharmaceutical agent Substances 0.000 description 7
239000006172 buffering agent Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 7
230000002335 preservative effect Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
239000001488 sodium phosphate Substances 0.000 description 5
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
CIWXXQSJBGNZNJ-UHFFFAOYSA-N BMS-192548 Chemical compound COC1=CC2=C(C(O)=C1)C(=O)C1=C(O)C3(O)C(=O)C(C(C)=O)=C(O)CC3(O)CC1=C2 CIWXXQSJBGNZNJ-UHFFFAOYSA-N 0.000 description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 4
229910000019 calcium carbonate Inorganic materials 0.000 description 4
235000010216 calcium carbonate Nutrition 0.000 description 4
229910000397 disodium phosphate Inorganic materials 0.000 description 4
235000019800 disodium phosphate Nutrition 0.000 description 4
230000000694 effects Effects 0.000 description 4
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 4
239000001095 magnesium carbonate Substances 0.000 description 4
229910000021 magnesium carbonate Inorganic materials 0.000 description 4
235000014380 magnesium carbonate Nutrition 0.000 description 4
229910000000 metal hydroxide Inorganic materials 0.000 description 4
150000004692 metal hydroxides Chemical class 0.000 description 4
230000000861 pro-apoptotic effect Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
235000017550 sodium carbonate Nutrition 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
239000011667 zinc carbonate Substances 0.000 description 4
229910000010 zinc carbonate Inorganic materials 0.000 description 4
235000004416 zinc carbonate Nutrition 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
150000004649 carbonic acid derivatives Chemical class 0.000 description 3
229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 3
125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
GKKPXBHNFVDHAQ-USNYZCROSA-N (2r)-n-[(2r)-3-[4-[n'-[[4-[(dimethylamino)methyl]cyclohexyl]methyl]carbamimidoyl]phenyl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]-2-(naphthalen-2-ylsulfonylamino)-3-phenylpropanamide Chemical compound C1CC(CN(C)C)CCC1CN=C(N)C(C=C1)=CC=C1C[C@H](C(=O)N1CCCC1)NC(=O)[C@H](NS(=O)(=O)C=1C=C2C=CC=CC2=CC=1)CC1=CC=CC=C1 GKKPXBHNFVDHAQ-USNYZCROSA-N 0.000 description 2
DSEJCLDJIFTPPH-FMIVXFBMSA-N (e)-n-(1-acetyl-2,3-dihydroindol-6-yl)-3-(3-cyanophenyl)-n-[1-(2-cyclopentylethyl)piperidin-4-yl]prop-2-enamide Chemical compound C1=C2N(C(=O)C)CCC2=CC=C1N(C(=O)\C=C\C=1C=C(C=CC=1)C#N)C(CC1)CCN1CCC1CCCC1 DSEJCLDJIFTPPH-FMIVXFBMSA-N 0.000 description 2
FBMCYYWIBYEOST-GJFSDDNBSA-N BIBO-3304 Chemical compound OC(=O)C(F)(F)F.N([C@H](CCCNC(=N)N)C(=O)NCC=1C=CC(CNC(N)=O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 FBMCYYWIBYEOST-GJFSDDNBSA-N 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
239000004283 Sodium sorbate Substances 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
239000003637 basic solution Substances 0.000 description 2
KUWBXRGRMQZCSS-HSZRJFAPSA-N bibp-3226 Chemical compound N([C@H](CCCN=C(N)N)C(=O)NCC=1C=CC(O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 KUWBXRGRMQZCSS-HSZRJFAPSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
RSJAXPUYVJKAAA-JPGJPTAESA-N biie-0246 Chemical compound N([C@@H](CCCN=C(N)N)C(=O)NCCN1C(N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C1=O)=O)C(=O)CC1(CC(=O)N2CCN(CC2)C2C3=CC=CC=C3C(=O)NC3=CC=CC=C32)CCCC1 RSJAXPUYVJKAAA-JPGJPTAESA-N 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
ZWGWSFHAZWNQQE-VPLSKCCHSA-N chembl1836102 Chemical compound Cl.C1=CC=C2C(N)=NC(NC[C@@H]3CC[C@@H](CNS(=O)(=O)C=4C=C5C=CC=CC5=CC=4)CC3)=NC2=C1 ZWGWSFHAZWNQQE-VPLSKCCHSA-N 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940125797 compound 12 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000008105 phosphatidylcholines Chemical class 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000013049 sediment Substances 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000008227 sterile water for injection Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
0 CC(COCCCCC1C(CC2)C(C3)[C@]4(C)C2C[C@](*)CC4)CO[C@@]1(C)C3=O Chemical compound CC(COCCCCC1C(CC2)C(C3)[C@]4(C)C2C[C@](*)CC4)CO[C@@]1(C)C3=O 0.000 description 1
BBKTULIRFCXDEB-IMJSIDKUSA-N C[C@@H]([C@@H]1CB1)N Chemical compound C[C@@H]([C@@H]1CB1)N BBKTULIRFCXDEB-IMJSIDKUSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229910019093 NaOCl Inorganic materials 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000005250 alkyl acrylate group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000000746 allylic group Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000003139 biocide Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000005907 ketalization reaction Methods 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
238000006772 olefination reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

CN201180072842.2A 2011-08-23 2011-08-23 脱氧胆酸和其盐的制剂 Pending CN103826608A (zh)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
CN201810400642.9A CN108619089A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂
CN201810403291.7A CN108743522A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2011/048806 WO2013028177A1 (en)	2011-08-23	2011-08-23	Formulations of deoxycholic acid and salts thereof

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201810403291.7A Division CN108743522A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂
CN201810400642.9A Division CN108619089A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂

Publications (1)

Publication Number	Publication Date
CN103826608A true CN103826608A (zh)	2014-05-28

Family

ID=45569726

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CN201180072842.2A Pending CN103826608A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂
CN201810400642.9A Pending CN108619089A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂
CN201810403291.7A Pending CN108743522A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CN201810400642.9A Pending CN108619089A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂
CN201810403291.7A Pending CN108743522A (zh)	2011-08-23	2011-08-23	脱氧胆酸和其盐的制剂

Country Status (18)

Country	Link
JP (1)	JP5919597B2 (es)
KR (5)	KR101751585B1 (es)
CN (3)	CN103826608A (es)
AU (3)	AU2011375432B2 (es)
BR (1)	BR112014000547B1 (es)
CA (1)	CA2842177C (es)
CR (1)	CR20140053A (es)
EA (1)	EA029305B1 (es)
IL (1)	IL230547A (es)
IN (1)	IN2014CN02188A (es)
MX (1)	MX350390B (es)
MY (1)	MY184277A (es)
NZ (1)	NZ620040A (es)
PH (2)	PH12014500240A1 (es)
SG (1)	SG2014013205A (es)
UA (1)	UA113522C2 (es)
WO (1)	WO2013028177A1 (es)
ZA (1)	ZA201401027B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107865964A (zh) *	2016-09-22	2018-04-03	李京洛	低渗性脂肪分解组合物及其制备方法
CN116617160A (zh) *	2023-07-25	2023-08-22	山东则正医药技术有限公司	水性混悬液及制备方法、冻干粉及应用、脂肪消减注射剂

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8101593B2 (en)	2009-03-03	2012-01-24	Kythera Biopharmaceuticals, Inc.	Formulations of deoxycholic acid and salts thereof
WO2012112940A1 (en)	2011-02-18	2012-08-23	Kythera Biopharmaceuticals, Inc.	Treatment of submental fat
JP2018532806A (ja) *	2015-11-04	2018-11-08	キセラバイオファーマシューティカルズインコーポレイテッド	デオキシコール酸およびその塩による蓄積脂肪の処置方法
KR101841193B1 (ko) *	2016-09-22	2018-03-22	이경락	저장성 지방 분해 조성물 및 그의 제조 방법
WO2019203511A1 (ko) *	2018-04-16	2019-10-24	주식회사 펜믹스	데옥시콜릭산을 포함하는 약학 조성물
KR102172439B1 (ko) *	2018-12-05	2020-10-30	송미희	지방 분해용 조성물 및 이를 포함하는 주사제 조성물
KR102064864B1 (ko)	2019-02-08	2020-01-10	(주)제테마	국소 주사용 조성물
KR102111346B1 (ko)	2019-08-20	2020-05-22	아영창	침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물
KR20220026068A (ko)	2020-08-25	2022-03-04	강명범	지방 분해용 주사제 조성물
CN118005707A (zh) *	2024-01-18	2024-05-10	山东省食品药品检验研究院	一种脱氧胆酸钠晶型a及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1348360A (zh) *	1998-07-24	2002-05-08	柳署弘	制备含有胆汁酸的澄清水溶液剂型
US6417179B1 (en) *	1998-10-13	2002-07-09	Craig G. Burkhart	Ear wax solution
US20050048126A1 (en) *	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754709B1 (fr)	1996-10-23	1999-03-05	Sanofi Sa	Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
DE10361067A1 (de) *	2003-12-22	2005-07-14	Aventis Pharma Deutschland Gmbh	Medikamentöse Lipolyse von Fettansammlungen
PT1758590E (pt)	2004-05-19	2011-11-15	Univ California	Utilização de um detergente para a remoção não cirúrgica de gordura
US7754230B2 (en)	2004-05-19	2010-07-13	The Regents Of The University Of California	Methods and related compositions for reduction of fat
US20060127468A1 (en)	2004-05-19	2006-06-15	Kolodney Michael S	Methods and related compositions for reduction of fat and skin tightening
AU2006255097B2 (en)	2005-06-06	2012-02-09	Georgetown University	Compositions and methods for lipo modeling
TW201011755A (en)	2008-09-10	2010-03-16	Skymedi Corp	Flash memory system and its data recovery method
JP5420946B2 (ja) *	2009-03-23	2014-02-19	富士フイルム株式会社	胆汁酸を含むミノキシジル水性組成物
EP2645099A1 (en) *	2012-03-30	2013-10-02	Phares Pharmaceutical Research N.V.	Biorelevant compositions

2011
- 2011-08-23 KR KR1020147006855A patent/KR101751585B1/ko not_active Expired - Fee Related
- 2011-08-23 KR KR1020207002722A patent/KR20200013103A/ko not_active Ceased
- 2011-08-23 AU AU2011375432A patent/AU2011375432B2/en active Active
- 2011-08-23 WO PCT/US2011/048806 patent/WO2013028177A1/en active Application Filing
- 2011-08-23 EA EA201490175A patent/EA029305B1/ru unknown
- 2011-08-23 KR KR1020177016779A patent/KR101919269B1/ko active Active
- 2011-08-23 CN CN201180072842.2A patent/CN103826608A/zh active Pending
- 2011-08-23 UA UAA201400641A patent/UA113522C2/uk unknown
- 2011-08-23 IN IN2188CHN2014 patent/IN2014CN02188A/en unknown
- 2011-08-23 JP JP2014527128A patent/JP5919597B2/ja not_active Expired - Fee Related
- 2011-08-23 KR KR1020197030233A patent/KR102073536B1/ko active Active
- 2011-08-23 CN CN201810400642.9A patent/CN108619089A/zh active Pending
- 2011-08-23 PH PH1/2014/500240A patent/PH12014500240A1/en unknown
- 2011-08-23 MX MX2014001495A patent/MX350390B/es active IP Right Grant
- 2011-08-23 CN CN201810403291.7A patent/CN108743522A/zh active Pending
- 2011-08-23 NZ NZ620040A patent/NZ620040A/en not_active IP Right Cessation
- 2011-08-23 SG SG2014013205A patent/SG2014013205A/en unknown
- 2011-08-23 CA CA2842177A patent/CA2842177C/en active Active
- 2011-08-23 MY MYPI2014000197A patent/MY184277A/en unknown
- 2011-08-23 KR KR1020187032491A patent/KR102034606B1/ko active Active
- 2011-08-23 BR BR112014000547-8A patent/BR112014000547B1/pt active IP Right Grant
2014
- 2014-01-20 IL IL230547A patent/IL230547A/en active IP Right Grant
- 2014-01-30 CR CR20140053A patent/CR20140053A/es unknown
- 2014-02-10 ZA ZA2014/01027A patent/ZA201401027B/en unknown
2016
- 2016-04-27 AU AU2016202661A patent/AU2016202661B2/en not_active Ceased
- 2016-06-16 PH PH12016501175A patent/PH12016501175B1/en unknown
2018
- 2018-04-23 AU AU2018202807A patent/AU2018202807B2/en not_active Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1348360A (zh) *	1998-07-24	2002-05-08	柳署弘	制备含有胆汁酸的澄清水溶液剂型
US6417179B1 (en) *	1998-10-13	2002-07-09	Craig G. Burkhart	Ear wax solution
US20050048126A1 (en) *	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADAM M. ROTUNDA ET AL.: "《Randomized Double-Blind Clinical Trial of Subcutaneously Injected Deoxycholate Versus a Phosphatidylcholine–Deoxycholate Combination for the Reduction of Submental Fat》", 《DERMATOLOGIC SURGERY》 *
ADAM M. ROTUNDA ET AL.: "《Randomized Double-Blind Clinical Trial of Subcutaneously Injected Deoxycholate Versus a Phosphatidylcholine–Deoxycholate Combination for the Reduction of Submental Fat》", 《DERMATOLOGIC SURGERY》, vol. 35, 31 December 2009 (2009-12-31) *
KYTHERA BIOPHARMACEUTICALS: "《Evaluation of Safety and Efficacy of ATX-101 in the Reduction of Submental Fat》", 《NCT01294644》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107865964A (zh) *	2016-09-22	2018-04-03	李京洛	低渗性脂肪分解组合物及其制备方法
CN116617160A (zh) *	2023-07-25	2023-08-22	山东则正医药技术有限公司	水性混悬液及制备方法、冻干粉及应用、脂肪消减注射剂

Also Published As

Publication number	Publication date
IN2014CN02188A (es)	2015-05-29
AU2016202661A1 (en)	2016-05-19
BR112014000547B1 (pt)	2021-11-09
NZ620040A (en)	2016-06-24
KR20170075016A (ko)	2017-06-30
JP2014524467A (ja)	2014-09-22
BR112014000547A2 (pt)	2017-02-14
AU2018202807A1 (en)	2018-05-10
KR102034606B1 (ko)	2019-10-22
EA029305B1 (ru)	2018-03-30
AU2011375432B2 (en)	2016-02-04
PH12016501175A1 (en)	2017-12-11
AU2011375432A1 (en)	2014-02-06
MX2014001495A (es)	2014-04-25
AU2016202661B2 (en)	2018-02-22
CN108743522A (zh)	2018-11-06
UA113522C2 (xx)	2017-02-10
KR20180123734A (ko)	2018-11-19
CR20140053A (es)	2014-06-12
KR20200013103A (ko)	2020-02-05
IL230547A (en)	2017-02-28
WO2013028177A1 (en)	2013-02-28
CN108619089A (zh)	2018-10-09
CA2842177C (en)	2016-07-19
PH12016501175B1 (en)	2017-12-11
MX350390B (es)	2017-09-06
KR101751585B1 (ko)	2017-06-27
KR20190119677A (ko)	2019-10-22
SG2014013205A (en)	2014-05-29
AU2018202807B2 (en)	2020-01-16
KR102073536B1 (ko)	2020-02-04
CA2842177A1 (en)	2013-02-28
KR101919269B1 (ko)	2018-11-15
KR20150000448A (ko)	2015-01-02
ZA201401027B (en)	2017-09-27
IL230547A0 (en)	2014-03-31
PH12014500240A1 (en)	2022-11-23
EA201490175A1 (ru)	2014-06-30
MY184277A (en)	2021-03-30
JP5919597B2 (ja)	2016-05-18

Publication	Publication Date	Title
US20210252021A1 (en)	2021-08-19	Formulations of deoxycholic acid and salts thereof
AU2018202807B2 (en)	2020-01-16	Formulations of deoxycholic acid and salts thereof
US20220072011A1 (en)	2022-03-10	Treatments of accumulated fat with deoxycholic acid and salts thereof
EP3305298B1 (en)	2019-05-01	Formulations of deoxycholic acid and salts thereof
JP6219430B2 (ja)	2017-10-25	デオキシコール酸およびその塩類の製剤
JP6594486B2 (ja)	2019-10-23	デオキシコール酸およびその塩類の製剤
JP6356329B2 (ja)	2018-07-11	デオキシコール酸およびその塩類の製剤
EA034320B1 (ru)	2020-01-28	Композиции дезоксихолата натрия

Legal Events

Date	Code	Title	Description
2014-05-28	C06	Publication
2014-05-28	PB01	Publication
2014-07-09	C10	Entry into substantive examination
2014-07-09	SE01	Entry into force of request for substantive examination
2018-10-19	RJ01	Rejection of invention patent application after publication
2018-10-19	RJ01	Rejection of invention patent application after publication	Application publication date: 20140528

CN103826608A - 脱氧胆酸和其盐的制剂 - Google Patents

Info

Links

Images

Classifications

Landscapes

Priority Applications (2)

Applications Claiming Priority (1)

Related Child Applications (2)

Publications (1)

Family

ID=45569726

Family Applications (3)

Family Applications After (2)

Country Status (18)

Cited By (2)

Families Citing this family (10)

Citations (3)

Family Cites Families (9)

Patent Citations (3)

Non-Patent Citations (3)

Cited By (2)

Also Published As

Similar Documents

Legal Events